Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Ariella who wrote (1079)	7/22/1998 12:39:00 PM
From: Zvi Steinberg	Respond to of 1491

Ariella, Pharmos had the right to receive an additional $3 MM from the CC group (NOT in the filing) but declined the money earlier this month as they (Pharmos) felt they didn't need the money. This may well be an indication that the co is confident enough that revenues from Lotemax and alrex should be sufficient to fund operations for a while. regarding the Co- partnering issue with BOL, the matter is still not resolved. BOL wants PARS to give up part of their royalty payments to sweeten the deal with co-marketing partner, but Pharmos will not do it as it sees no justification for it. This has been going on for almost a month. The CC group has converted some of their pfds to stock as of last Friday, but not much. Kol Tuv, Zvi

To: Ariella who wrote (1079)	7/22/1998 4:43:00 PM
From: yosi s	Read Replies (1) \| Respond to of 1491

There is a lot of discusion on the thread but do not lose sight. Alrex and Lotemax are on the market. It takes a little time, for prescription habits to change. But with its safety profile both meds will continue to gain market share, thus providing PARS with steady predictable growth. It takes minimum 6 month of marketing to establish a trend of sales and 2 yrs to see where it is growing. To that you can add step wise Europeen introduction. increase revenues built in. Then Tobra Alrex combination will add revenues. That is in. As for the price it is the same story as'before FDA final approval. but this time it is Castle Creck. HU211 is the wild card. If the news as I expect is positive and if PARS will get the media coverage it deserves than the PARS will be Discovered. Otherwise it will take a bit longer. The potential market for hu211 is HUGE . and here we have a biotech that is about to make money, with a pipeline that is to be "discovered" that is why the price is languishing. The company had no bad news. And the future is bright and revenues stream is here. So it is probabbly one of the best buys there ever was. Best Regards Yosi.